These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 33323024

  • 1. Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.
    Papasavvas E, Azzoni L, Pagliuzza A, Abdel-Mohsen M, Ross BN, Fair M, Howell BJ, Hazuda DJ, Chomont N, Li Q, Mounzer K, Kostman JR, Tebas P, Montaner LJ.
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):433-443. PubMed ID: 33323024
    [Abstract] [Full Text] [Related]

  • 2. NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.
    Papasavvas E, Azzoni L, Kossenkov AV, Dawany N, Morales KH, Fair M, Ross BN, Lynn K, Mackiewicz A, Mounzer K, Tebas P, Jacobson JM, Kostman JR, Showe L, Montaner LJ.
    J Immunol; 2019 Aug 01; 203(3):705-717. PubMed ID: 31253727
    [Abstract] [Full Text] [Related]

  • 3. Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption.
    Papasavvas E, Azzoni L, Ross BN, Fair M, Howell BJ, Hazuda DJ, Mounzer K, Kostman JR, Tebas P, Montaner LJ.
    AIDS; 2021 Oct 01; 35(12):2051-2054. PubMed ID: 34049356
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.
    Hua S, Vigano S, Tse S, Zhengyu O, Harrington S, Negron J, Garcia-Broncano P, Marchetti G, Genebat M, Leal M, Resino S, Ruiz-Mateos E, Lichterfeld M, Yu XG.
    Clin Infect Dis; 2018 Jun 01; 66(12):1910-1917. PubMed ID: 29272392
    [Abstract] [Full Text] [Related]

  • 7. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellón JM, Esteban H, GESIDA HIV/HCV cohort.
    J Antimicrob Chemother; 2009 Jun 01; 63(6):1256-63. PubMed ID: 19363085
    [Abstract] [Full Text] [Related]

  • 8. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
    Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, Daurès JP, Blanc P.
    Drugs; 2013 Mar 01; 73(3):263-77. PubMed ID: 23436591
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.
    J Gastroenterol Hepatol; 2008 Jun 01; 23(6):861-6. PubMed ID: 18422960
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF, Sun HQ, Huang Q, Wang JR, Zhang XX, Liu XN, Ma Q, Lu HZ.
    Haemophilia; 2010 May 01; 16(3):502-7. PubMed ID: 20028427
    [Abstract] [Full Text] [Related]

  • 12. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.
    Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB, AIDS Clinical Trials Group A5192 Team.
    J Infect Dis; 2010 Jun 01; 201(11):1686-96. PubMed ID: 20420510
    [Abstract] [Full Text] [Related]

  • 13. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.
    J Womens Health (Larchmt); 2015 Feb 01; 24(2):159-64. PubMed ID: 25682817
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group.
    Antivir Ther; 2005 Feb 01; 10(2):309-17. PubMed ID: 15865225
    [Abstract] [Full Text] [Related]

  • 16. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.
    Goujard C, Emilie D, Roussillon C, Godot V, Rouzioux C, Venet A, Colin C, Pialoux G, Girard PM, Boilet V, Chaix ML, Galanaud P, Chene G, ANRS-112 INTERPRIM Study Group.
    AIDS; 2012 Sep 24; 26(15):1895-905. PubMed ID: 22842994
    [Abstract] [Full Text] [Related]

  • 17. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
    ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, Flisiak R, van' t Veen A, de Man RA, Schalm SW, Janssen HL, Haagmans BL, HBV 99-01 Study Group.
    Antivir Ther; 2007 Sep 24; 12(8):1285-94. PubMed ID: 18240868
    [Abstract] [Full Text] [Related]

  • 18. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Moreno L, Quereda C, Moreno A, Perez-Elías MJ, Antela A, Casado JL, Dronda F, Mateos ML, Bárcena R, Moreno S.
    AIDS; 2004 Jan 02; 18(1):67-73. PubMed ID: 15090831
    [Abstract] [Full Text] [Related]

  • 19. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group.
    Clin Infect Dis; 2014 Dec 15; 59(12):1768-76. PubMed ID: 25139963
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.